Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Contact Email
Phone number
Website URL
Similar Companies1000
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics to treat healthcare problems.
Sector
Subsector
Location
total rounds
total raised
Kinarus Therapeutics (SIX:KNRS)
Kinarus Therapeutics is a pharmaceutical company developing innovative treatments for viral, respiratory and ophthalmic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Spexis
Spexis is a Swiss biopharmaceutical company that develops transformative biotechnological medicines.
Sector
Subsector
Keywords
Location
Financials
Funding Rounds10
Number of Funding Rounds
Money Raised
Their latest funding was raised on 26.09.2017. Their latest round Post-IPO Equity
Co-Investors
Investors5
Number of lead investors
Number of investors
3i Group
3i is a British private equity group that invests in and supports businesses.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Apax Partners
Apax Partners is a global private equity firm focused on long-term investment in growth companies.
Sector
Subsector
Location
total rounds
count Of Investments
count Of Exists
Acquisitions2
NeuroNova acquired by Newron Pharmaceuticals
acquirer
date
type
NeuroNova
NeuroNova is a company that develops drug targets and candidates for the treatment of neurodegenerative diseases.
Sector
Subsector
Location
Hunter-Fleming Ltd acquired by Newron Pharmaceuticals
acquirer
date
type
Hunter-Fleming Ltd
Hunter-Fleming Ltd develops medicines for neurodegenerative and inflammatory disorders.
Sector
Subsector
Location
People
Founders1
Luca Benatti
Luca Benatti is the Chief Executive Officer since June 2012. He has 27 year experience in Pharma and Biotech. He was Co-founder, CEO and Member of the Board of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound safinamide now approaching worldwide regulatory filing for the treatment of Parkinson's disease. During his tenure, Newron raised significant capital from international venture capital firms, and was listed at the Swiss stock exchange. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon, and in the acquisition of the UK biotech Company Hunter Fleming. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Newron (Swiss Stock Exchange), Intercept Pharmaceuticals (Nasdaq), Chairman of the Scientific Advisory Board of Zambon, Vice President and member of the Board of Assobiotec and member of the Jury of the European Biotechnica Award. He has authored several scientific publications and holds numerous patents.
current job
organization founded
Luca Benatti
Employee Profiles7
Activity
Recent News6
The graph reveals the ratio (%) of positive news articles in a chosen time range